Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0633 in Patients With COPD
NCT00418613Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2008
- Primary completion
- Mar 2009
01
Overview
A Phase 2 trial of setileuton in chronic obstructive pulmonary disease (COPD), sponsored by Merck & Co.. Started Jan 2008; status: completed.
02
Drugs
setileuton
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00418613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418613.